ValuEngine upgraded shares of Insys Therapeutics (NASDAQ:INSY) from a sell rating to a hold rating in a research report sent to investors on Friday, December 29th.
INSY has been the topic of several other research reports. Zacks Investment Research upgraded Insys Therapeutics from a hold rating to a buy rating and set a $8.50 price target on the stock in a research note on Tuesday, October 24th. Royal Bank of Canada set a $8.00 target price on Insys Therapeutics and gave the company a buy rating in a research note on Friday, October 27th. Oppenheimer reissued a hold rating on shares of Insys Therapeutics in a report on Sunday, November 12th. Finally, Jefferies Group lowered their price target on Insys Therapeutics from $14.00 to $11.00 and set a buy rating for the company in a report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $9.38.
Insys Therapeutics (INSY) opened at $8.84 on Friday. The company has a market capitalization of $648.12, a price-to-earnings ratio of -3.47 and a beta of 0.76. Insys Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.02.
A number of hedge funds have recently made changes to their positions in INSY. Alliancebernstein L.P. raised its position in Insys Therapeutics by 128.6% during the second quarter. Alliancebernstein L.P. now owns 140,840 shares of the specialty pharmaceutical company’s stock valued at $1,782,000 after acquiring an additional 79,220 shares in the last quarter. Quantitative Investment Management LLC purchased a new position in Insys Therapeutics during the second quarter valued at approximately $879,000. Schneider Capital Management Corp increased its position in shares of Insys Therapeutics by 100.0% in the second quarter. Schneider Capital Management Corp now owns 119,973 shares of the specialty pharmaceutical company’s stock valued at $1,518,000 after buying an additional 60,000 shares in the last quarter. Marshall Wace North America L.P. purchased a new stake in shares of Insys Therapeutics in the second quarter valued at approximately $612,000. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Insys Therapeutics by 31.1% in the third quarter. Schwab Charles Investment Management Inc. now owns 104,812 shares of the specialty pharmaceutical company’s stock valued at $931,000 after buying an additional 24,869 shares in the last quarter. Institutional investors own 25.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Insys Therapeutics (INSY) Stock Rating Upgraded by ValuEngine” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/14/insys-therapeutics-insy-upgraded-by-valuengine-to-hold.html.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.